Tech Company Financing Transactions
Affinivax Funding Round
Affinivax closed a $4 million venture capital round on 10/31/2014. Backers included Bill & Melinda Gates Foundation.
Transaction Overview
Company Name
Announced On
10/31/2014
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to develop its Multiple Antigen Presenting System (MAPS) technology platform and enable the development of novel vaccines to protect children and adults in both the developed and developing worlds, with an initial focus on its lead drug program for Streptococcus pneumoniae (pneumococcus).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
301 Binney St. 302
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Affinivax is developing a next generation vaccine technology platform based on its proprietary platform, the Multiple Antigen Presenting System (MAPS).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Brugger
Chief Operating Officer
Kamran Tavangar
VP - Finance
Joseph Straight
VP - Human Resources
Ann Straight
VP - Product Management
Shite Sebastian
VP - R & D
Gilles Besin
VP - Regulatory Affairs
Frank Malinoski
Browse more venture capital transactions:
Prev: 10/31/2014: Cursive Labs venture capital transaction
Next: 10/31/2014: Peraso Technologies venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs